

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Attorney Docket No.

50201/003002

Serial No.

10/817,248

Applicant

Abdel-Meguid et al.

Filing Date

April 2, 2004

Group

1815 1654

IDS Filed

November 8, 2004

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 C.F.R. § 1.98(b))

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
AK	4,904,659	02/27/90	Atwell et al.	514	235.2	10/28/88
	5,658,902	08/19/97	Ahn et al.	51	234.8	12/22/94
	5,942,620	08/24/99	Krantz et al.	546	166	07/01/98
	6,258,822	07/10/01	Geyer et al.	514	275	08/06/98
AK	6,284,796	09/04/01	Geyer et al.	514	275	08/06/98

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
AK	WO 96/18644	06/20/96	WIPO			
	WO 00/32590	06/08/00	WIPO			
	WO 00/66545	11/09/00	WIPO			No, Abstract in English
	WO 00/69832	11/23/00	WIPO			
	WO 02/24667	03/28/02	WIPO			
AK	EP 0206802	09/01/93	EPO			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

AK	Granberg et al., X-ray crystallographic studies of des-Gla-FVIIa/sTF complexes and their use in structure based design. Poster MEDI 85 American Chemical Society 226 th National Meeting, September 8, 2003.
	Holmes et al., "Site specific 1:1 opioid:albumin conjugate with in vitro activity and long in vivo duration," <i>Bioconj. Chem.</i> 11(4):439-444 (2000).
	Johansson-Zetterberg et al., Search for bensamidine P1- replacement in FVIIa dipeptide inhibitors. Poster MEDI 83 American Chemical Society 226 th National Meeting, September 8, 2003.
	Klinghofer et al., "Species specificity of amidine-based urokinase inhibitors," <i>Biochemistry</i> 40(31):9125-9131 (2001).
AK	Meijers et al., "High levels of coagulation factor XI as a risk factor for venous thrombosis," <i>N. Engl. J. Med.</i> 342(10):696-701 (2000).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50201/003002 Serial No. 10/817,248 Applicant Abdel-Meguid et al. Filing Date April 2, 2004 Group 1614 1654 IDS Filed November 8, 2004
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		
(37 C.F.R. § 1.98(b))		
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)		
ADK	Outt et al., "A General Synthesis of 4-Substituted 6-(2-Imidazolinyllamino)-5,8-dimethylquinolines," <i>J. Org. Chem.</i> 63(17):5762-5768 (1998).	
ADK	Parlow et al., "Polymer-assisted solution-phase library synthesis and crystal structure of alpha-ketothiazoles as tissue factor VIIa inhibitors," <i>J. Med. Chem.</i> 46(19):4043-4049 (2003).	
ADK	Veale et al., "Nonpeptidic inhibitors of human leukocyte elastase.5.Design, synthesis, and X-ray crystallography of a series of orally active 5-aminopyrimidin-6-one-containing trifluoromethyl ketones," <i>J. Med. Chem.</i> 38(1):98-108 (1995).	
EXAMINER	ADK	DATE CONSIDERED 7/29/04
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.		